NanoVibronix Partners with Fabrication Enterprises, Inc. for Distribution of PainShield® in the United States
May 09 2018 - 7:00AM
NanoVibronix, Inc.,
(NASDAQ:NAOV)
, a medical device company utilizing
the Company’s proprietary and patented low intensity surface
acoustic wave (SAW) technology, today announced it has partnered
with Fabrication Enterprises, Inc. to market and distribute
NanoVibronix’s PainShield® in the U.S., with a focus on the sports
medicine, sports trainer, and physical therapy markets.
Fabrication Enterprises is a leading
manufacturer, importer, and master distributor of products for
physical therapy, occupational therapy, chiropractic clinics,
athletic training, homecare, and more. Founded in 1974, its
products are sold to hospitals, clinics, fitness centers, and
professionals through a global network of dealers.
In addition, both NanoVibronix and Fabrication
Enterprises will feature the product at their respective booths at
the NATA 69th Clinical Symposia & AT Expo, which is being held
June 26-29 in New Orleans. NATA 2018 is hosted by the National
Athletic Trainers’ Association (NATA) and is one of the premier
industry conferences targeting the athletic training
profession.
Exhibitor booth:
- Fabrication Enterprises, Inc: #4063
- NanoVibronix: #1021
Elliott Goldberg, President of Fabrication
Enterprises, Inc., stated, “Trainers have a very personal
relationship with their clients that often provides them intimate
knowledge of their clients’ unique conditions. PainShield has been
clinically proven to treat certain types of pain and induce soft
tissue healing in targeted areas, which is particularly well-suited
for the sports medicine and sports trainer markets. Given the fact
it is portable, lightweight, and does not require administration by
medical personnel, PainShield can therefore be used by the
trainers’ clients without being located in a health care facility
or clinic. The advantages of the product are further highlighted by
the growing support from a number of professional athletes who have
witnessed the benefits of PainShield firsthand and have publicly
endorsed the product. We look forward to featuring PainShield at
the upcoming NATA 69th Clinical Symposia & AT Expo.”
Brian Murphy, CEO of NanoVibronix, commented,
“We are excited to partner with Fabrication Enterprises, a leading
distributor of medical devices in the U.S. with over 18 sales
representatives and a network of global distributors. This
partnership further illustrates the growing interest in PainShield
within the personal training sports medicine market. According to
the U.S. Bureau of Labor Statistics, the number of personal
training jobs in the United States is slated to grow about 10
percent per year with over 330,000 personal training jobs
forecasted by 2026. Many of these trainers work in health clubs,
fitness or recreation centers, gyms, country clubs, hospitals,
group fitness studios, resorts and at clients’ homes, making ideal
points of contact with the end user.”
PainShield is an ultrasound device, consisting
of a reusable driver unit and a disposable patch, which contains a
proprietary therapeutic transducer. PainShield delivers a localized
ultrasound effect to treat pain and induce soft tissue healing in a
targeted area, while keeping the level of ultrasound energy at a
safe and consistent level. Its range of applications includes acute
and chronic pain resolution through its many mechanisms of action.
The product has been acknowledged by several sports icons and has
broad applications for sports injuries. PainShield can be used by
patients at home or work or in a clinical setting and can be used
even while the patient is sleeping. Patient benefits include ease
of application and use, faster recovery time, high compliance, and
increased safety and efficacy over existing devices that rely on
higher-frequency ultrasound.
About NanoVibronix
NanoVibronix Inc. (NASDAQ:NAOV) is a medical device company
headquartered in Elmsford, NY with research and development in
Nesher, Israel, that is focused on developing medical devices
utilizing its proprietary and patented low intensity surface
acoustic wave technology. The company's technology allows for the
creation of low-frequency ultrasound waves that can be utilized for
a variety of medical applications, including the disruption of
biofilms and bacteria colonization, as well as providing pain
relief. The devices can be administered at home without the
assistance of medical professionals. The company's primary products
include PainShield®, UroShield™ and WoundShield™. Additional
information about the company is available at:
www.nanovibronix.com.
Forward-looking StatementsThis press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward-looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) market acceptance of our existing and new
products, (ii) negative clinical trial results or lengthy product
delays in key markets, (iii) an inability to secure regulatory
approvals for the sale of our products, (iv) intense competition in
the medical device industry from much larger, multinational
companies, (v) product liability claims, (vi) product malfunctions,
(vii) our limited manufacturing capabilities and reliance on
subcontractors for assistance, (viii) insufficient or inadequate
reimbursement by governmental and other third party payers for our
products, (ix) our efforts to successfully obtain and maintain
intellectual property protection covering our products, which may
not be successful, (x) legislative or regulatory reform of the
healthcare system in both the U.S. and foreign jurisdictions, (xi)
our reliance on single suppliers for certain product components,
(xii) the fact that we will need to raise additional capital to
meet our business requirements in the future and that such capital
raising may be costly, dilutive or difficult to obtain and (xiii)
the fact that we conduct business in multiple foreign
jurisdictions, exposing us to foreign currency exchange rate
fluctuations, logistical and communications challenges, burdens and
costs of compliance with foreign laws and political and economic
instability in each jurisdiction. More detailed information about
the Company and the risk factors that may affect the realization of
forward looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s web site at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Investor Contacts:Crescendo
Communicationsnaov@crescendo-ir.com(212) 671-1021
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Jun 2024 to Jul 2024
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Jul 2023 to Jul 2024